Advancing Sickle Cell Research

About oneSCDvoice

oneSCDvoice was created with the vision of empowering those impacted by sickle cell disease through facilitating access to information and support from the sickle cell disease community.

This innovative digital education platform was developed in collaboration with the community, including our working groups of more than 20 sickle cell disease patients, advocates, and medical professionals, as well as members from the Sickle Cell Disease Association of America, and rareLife solutions. Building off of rareLife’s “onevoice” community technology, the collaboration members guided the customization of the platform by identifying knowledge gaps, sharing information preferences, and continually engaging their networks for additional insights.

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA’s mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.

We hope you find the oneSCDvoice platform helpful to you. Please click here to share any feedback, questions, or any general comments. You can also find answers to important questions on topics such as privacy and security in our Frequently Asked Questions.

The oneSCDvoice Team

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.